Xcout Intel
Oncolytics Biotech Inc.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously administered therapeutic. The company focuses on unleashing the power of the immune system and operates as a public company with a small team based in San Diego, California.
Subscribe to see Oncolytics Biotech Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Oncolytics Biotech Inc. at a glance
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (ONCY) with a market capitalisation of $55.9M. Xcout tracks 22 named people at Oncolytics Biotech Inc., including Jared Kelly (Chief Executive Officer & Director).
Oncolytics Biotech Inc. leadership
- Jared KellyChief Executive Officer & Director
- John McAdoryChief Operating Officer
- Kirk J. LookChief Financial Officer
- Kirk LookChief Financial Officer
- Allison HagermanChief Technology Officer
- Thomas C. HeinemanChief Medical Officer
16 more named people on record for Oncolytics Biotech Inc., with roles, board committees and tenure — see the full roster →
Oncolytics Biotech Inc. competitors
A few of Oncolytics Biotech Inc.'s closest competitors — see the full list of competitors and alternatives →
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. Its proprietary T-win® technology is designed to modulate the tumor microenvironment by targeting both tumor cells and immune-suppressive cells, aiming to improve treatment outcomes for patients with melanoma and other tumor types.
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Western Oncolytics Ltd. is a cutting-edge biotechnology and pharmaceutical company headquartered in Pittsburgh, Pennsylvania, focused on developing novel cancer therapies and drug pipelines.
Get Oncolytics Biotech Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Oncolytics Biotech Inc. in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access